PCVX
LONGINSIDER SELLVAXCYTE INC
Research: Finviz ↗·Perplexity ↗
🗄 Viewing archived Q1 2026 data — frozen, no longer refreshed.
News Summary
NeutralVaxcyte advanced VAX-31 Phase 3 adult trials (OPUS-1 topline in Q4 2026, enabling potential 2027 BLA submission) and initiated VAX-A1 Phase 1 for Group A Strep, supported by a strong $2.51B cash position post-$600M capital raise. However, the company is burning cash at an alarming rate (~$513M in H1 2026 alone) with R&D expenses exceeding $580M annualized, and non-cancelable manufacturing commitments of $670M create significant execution risk if clinical programs underperform.
Red flags
- •Extreme cash burn: $513M in operating cash outflow in first half 2026 alone; at this rate, $2.5B cash covers only ~5 years despite 12-month guidance language
- •Non-cancelable manufacturing commitments of $670.2M create major financial inflexibility if clinical programs fail or face delays
- •Net losses accelerating: Q2 2026 loss of $284.3M vs. $166.6M YoY represents 71% increase despite no revenue generation
- •VAX-31 adult Phase 3 data not until Q4 2026 (OPUS-1) with full readout delayed to H1 2027, pushing any BLA submission well into 2027 with regulatory approval uncertainty
- •Infant Phase 2 data also delayed to end of H1 2027, further extending commercialization timeline
- •Early-stage VAX-A1 (GAS) won't have Phase 1 data until H2 2027, offering limited near-term value catalysts
Funds Buying (3)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Maverick Capital | Lee Ainslie | 1.4M | +24K | $80M | 0.9% | +2% | Existing |
| Baupost Group | Seth Klarman | 800K | +800K | $46M | 0.9% | — | NEW |
| Point72 | Steve Cohen | 620K | +620K | $36M | <0.1% | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.
Portfolio Context
Where PCVX ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.
position #21 of this fund's book
- 18MOLINA HEALTHCARE INC$84M
- 19GRUPO AEROMEXICO SAB DE CV$68M
- 20NORWEGIAN CRUISE LINE HLDGS$68M
- 21VAXCYTE INC$46M
- 22DNOW INC$43M
position #35 of this fund's book
- 32PHILIP MORRIS INTL INC$94M
- 33MCDONALDS CORP$91M
- 34MOLINA HEALTHCARE INC$86M
- 35VAXCYTE INC$80M
- 36NOVO-NORDISK A S$76M
- 37WAVE LIFE SCIENCES LTD$74M
- 38CENTESSA PHARMACEUTICALS PLC$74M
Values are quarter-end position sizes. Shown only for funds where PCVX ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| Dhaliwal Harpreet S. | Chief Technical Ops Officer | SELL | 17K | $55.00 | $0.94M | 2026-08-05 | ↗ |
| Wassil Jim | CHIEF OPERATING OFFICER | SELL | 861 | $53.50 | $0.05M | 2026-08-03 | ↗ |
| Wassil Jim | CHIEF OPERATING OFFICER | SELL | 1K | $54.09 | $0.08M | 2026-08-03 | ↗ |
| GUGGENHIME ANDREW | PRESIDENT AND CFO | SELL | 7K | $53.76 | $0.37M | 2026-08-03 | ↗ |
| GUGGENHIME ANDREW | PRESIDENT AND CFO | SELL | 3K | $54.18 | $0.16M | 2026-08-03 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 12K | $55.52 | $0.65M | 2026-07-27 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 4K | $55.93 | $0.25M | 2026-07-27 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 756 | $55.52 | $0.04M | 2026-07-27 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 244 | $55.96 | $0.01M | 2026-07-27 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 622 | $55.54 | $0.03M | 2026-07-27 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 378 | $55.91 | $0.02M | 2026-07-27 | ↗ |
| GUGGENHIME ANDREW | PRESIDENT AND CFO | SELL | 8K | $57.16 | $0.45M | 2026-07-06 | ↗ |
| GUGGENHIME ANDREW | PRESIDENT AND CFO | SELL | 2K | $57.76 | $0.12M | 2026-07-06 | ↗ |
| Wassil Jim | CHIEF OPERATING OFFICER | SELL | 2K | $56.03 | $0.10M | 2026-07-01 | ↗ |
| Wassil Jim | CHIEF OPERATING OFFICER | SELL | 456 | $57.47 | $0.03M | 2026-07-01 | ↗ |
| Wassil Jim | CHIEF OPERATING OFFICER | SELL | 6 | $57.82 | $0.00M | 2026-07-01 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 7K | $54.27 | $0.36M | 2026-06-26 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 9K | $55.27 | $0.50M | 2026-06-26 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 6K | $56.12 | $0.36M | 2026-06-26 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 312 | $54.34 | $0.02M | 2026-06-26 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 356 | $55.23 | $0.02M | 2026-06-26 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 332 | $55.99 | $0.02M | 2026-06-26 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 207 | $54.22 | $0.01M | 2026-06-26 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 602 | $55.30 | $0.03M | 2026-06-26 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 191 | $56.27 | $0.01M | 2026-06-26 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 225 | $52.51 | $0.01M | 2026-06-18 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 22K | $52.50 | $1.17M | 2026-06-18 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 1K | $52.50 | $0.05M | 2026-06-18 | ↗ |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | SELL | 1K | $52.50 | $0.05M | 2026-06-18 | ↗ |
| GUGGENHIME ANDREW | PRESIDENT AND CFO | SELL | 10K | $53.00 | $0.53M | 2026-06-18 | ↗ |
| Wassil Jim | CHIEF OPERATING OFFICER | SELL | 2K | $49.40 | $0.10M | 2026-06-01 | ↗ |
| Wassil Jim | CHIEF OPERATING OFFICER | SELL | 301 | $50.26 | $0.02M | 2026-06-01 | ↗ |
| Wassil Jim | CHIEF OPERATING OFFICER | SELL | 2K | $56.83 | $0.13M | 2026-05-01 | ↗ |
| Cowan Elvia | SVP, Finance & CAO | SELL | 3K | $60.00 | $0.18M | 2026-04-07 | ↗ |
| Wassil Jim | CHIEF OPERATING OFFICER | SELL | 1K | $58.14 | $0.08M | 2026-04-01 | ↗ |
| Wassil Jim | CHIEF OPERATING OFFICER | SELL | 838 | $58.93 | $0.05M | 2026-04-01 | ↗ |
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | SC 13G/A | 11.3M | 8.6% | 2026-02-17 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.